Literature DB >> 27432808

Persistent triple antiphospholipid antibody positivity as a strong risk factor of first thrombosis, in a long-term follow-up study of patients without history of thrombosis or obstetrical morbidity.

C M Yelnik1,2, G Urbanski2, E Drumez3, V Sobanski1,2, H Maillard1,2, A Lanteri1,2, S Morell-Dubois1,2, C Caron4, S Dubucquoi1,5, D Launay1,2, A Duhamel3, E Hachulla1,2, P Y Hatron1,2, M Lambert1,2.   

Abstract

Introduction The long-term risk of first thrombosis and benefit of prophylaxis in antiphospholipid antibody (aPL) carriers without history of thrombosis or obstetrical morbidity is poorly known. This study aimed to evaluate the long-term rate and risk factors associated with a first thrombosis in those patients. Patients and methods After a prior study ended in December 2005 and was already published, we extended the follow-up period of our cohort of aPL carriers. Results Ninety-eight of the 103 patients of the previous study were included. The annual first thrombosis rate was 2.3% per patient-year during a median of 13 years (6-17). None of the baseline characteristics was predictive of risk of first thrombosis, but persistent aPL over time were associated with an increased risk. The stronger association was found in triple aPL-positive carriers: OR 3.38 (95% CI: 1.24-9.22). Of note, conversely to our previous findings, no benefit of aspirin prophylaxis was observed. Conclusion The risk of first thrombosis in aPL carriers without history of thrombosis or obstetrical morbidity was significant, persisted linearly over time and was associated with persistent aPL. This risk was especially increased in triple aPL-positive carriers, in whom a close follow-up seems to be necessary. Nevertheless, the benefit of aspirin prophylaxis remained unclear.

Entities:  

Keywords:  Antiphospholipid antibody; anti-beta2 glycoprotein I antibody; anticardiolipin antibody; antiphospholipid syndrome; aspirin; lupus anticoagulant; prevention; thrombosis; triple positivity

Mesh:

Substances:

Year:  2016        PMID: 27432808     DOI: 10.1177/0961203316657433

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  12 in total

Review 1.  Clinical Risk Assessment in the Antiphospholipid Syndrome: Current Landscape and Emerging Biomarkers.

Authors:  Shruti Chaturvedi; Keith R McCrae
Journal:  Curr Rheumatol Rep       Date:  2017-07       Impact factor: 4.592

Review 2.  New insights into the pathogenic mechanisms and treatment of arterial thrombosis in antiphospholipid syndrome.

Authors:  Yuichiro Fujieda; Olga Amengual
Journal:  Eur J Rheumatol       Date:  2020-11-19

Review 3.  Laboratory Diagnosis of Antiphospholipid Syndrome: Insights and Hindrances.

Authors:  Arne Vandevelde; Katrien M J Devreese
Journal:  J Clin Med       Date:  2022-04-13       Impact factor: 4.964

Review 4.  Primary Thrombosis Prophylaxis in Persistently Antiphospholipid Antibody-Positive Individuals: Where Do We Stand in 2018?

Authors:  Yu Zuo; Medha Barbhaiya; Doruk Erkan
Journal:  Curr Rheumatol Rep       Date:  2018-09-10       Impact factor: 4.592

5.  Elevated plasma level of soluble triggering receptor expressed on myeloid cells-1 is associated with inflammation activity and is a potential biomarker of thrombosis in primary antiphospholipid syndrome.

Authors:  Yonatan Edel; Vitaly Kliminski; Elisheva Pokroy-Shapira; Shirly Oren; Ariela Dortort Lazar; Yael Pri-Paz Basson; Mohammad Egbaria; Yair Molad
Journal:  Arthritis Res Ther       Date:  2019-01-07       Impact factor: 5.156

6.  Prevalence of antiphospholipid antibodies in Behçet's disease: A systematic review and meta-analysis.

Authors:  Md Asiful Islam; Sayeda Sadia Alam; Shoumik Kundu; A H M Safayet Ullah Prodhan; Shahad Saif Khandker; Tatiana Reshetnyak; Przemysław J Kotyla; Rosline Hassan; Tareq Hossan
Journal:  PLoS One       Date:  2020-01-13       Impact factor: 3.240

Review 7.  Molecular Mechanisms of "Antiphospholipid Antibodies" and Their Paradoxical Role in the Pathogenesis of "Seronegative APS".

Authors:  Roberta Misasi; Agostina Longo; Serena Recalchi; Daniela Caissutti; Gloria Riitano; Valeria Manganelli; Tina Garofalo; Maurizio Sorice; Antonella Capozzi
Journal:  Int J Mol Sci       Date:  2020-11-09       Impact factor: 5.923

8.  Non-criteria manifestations in primary antiphospholipid syndrome: a French multicenter retrospective cohort study.

Authors:  Alexis F Guédon; Jennifer Catano; Laure Ricard; Charlotte Laurent; Claire de Moreuil; Geoffrey Urbanski; Sophie Deriaz; Grigorios Gerotziafas; Ismail Elalamy; Alexandra Audemard; Francois Chasset; Sonia Alamowitch; Jérémie Sellam; François Maillot; Jean Jacques Boffa; Ariel Cohen; Noémie Abisror; Olivier Fain; Arsène Mekinian
Journal:  Arthritis Res Ther       Date:  2022-01-25       Impact factor: 5.156

9.  Evaluation of Frequency, Clinical Correlation, and Antibodies Confirmation Profile in Patients with Suspected Antiphospholipid Syndrome.

Authors:  Filipe F Martins; Teresa M L Campos
Journal:  TH Open       Date:  2021-10-19

10.  Profiles of criteria and non-criteria anti-phospholipid autoantibodies are associated with clinical phenotypes of the antiphospholipid syndrome.

Authors:  Ilan Volkov; Luciana Seguro; Elaine P Leon; László Kovács; Dirk Roggenbuck; Peter Schierack; Boris Gilburd; Andrea Doria; Maria G Tektonidou; Nancy Agmon-Levin
Journal:  Auto Immun Highlights       Date:  2020-05-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.